Amgen disputing payments to Mass General

Lawyers for Amgen have triggered a ruckus with Massachusetts General Hospital over royalties for its blockbuster rheumatoid arthritis drug Enbrel. Amgen paid Mass General $41 million in royalties last year alone for its role in developing the drug, but lawyers for Amgen, which purchased the drug when it bought Immunex in 2001, say they've found language in the contract that is open to interpretation. Mass General says it doesn't read the contract that way. The payments have been used to fund the genetics laboratory of Brian Seed, a Harvard biophysicist whose work contributed to the development of Enbrel.

- read this story from the Boston Globe for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.